Kimyrsa
Payments companies reported to CMS as associated with Kimyrsa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Kimyrsa, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Kimyrsa
These are the largest totals companies reported as associated with Kimyrsa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Matthew Wikler | San Diego, CA | Infectious Disease | $98,361.50 |
| Andrew Dold | Dacula, GA | Infectious Disease | $43,898.08 |
| Shaker Itani | Las Vegas, NV | Infectious Disease | $25,938.63 |
| Guillermo Padilla-Pineda | Shreveport, LA | Infectious Disease | $23,858.81 |
| Thuan Le | Murrieta, CA | Infectious Disease | $21,058.71 |
| Miguel Sierra-Hoffman | Victoria, TX | Infectious Disease | $19,233.33 |
| Dino Delaportas | Bridgeport, WV | Infectious Disease | $17,608.82 |
| Fares Khater | Whitesburg, KY | Internal Medicine | $16,205.07 |
| Stephen Weinroth | Fairfax, VA | Infectious Disease | $16,099.78 |
| Jeffrey Alexander | Chicago, IL | Foot & Ankle Surgery | $12,561.65 |
Prescribed Kimyrsa?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.